Dawson James Securities Announces the Closing of Oversubscribed $10,350,000 Rights Offering for PAVmed, Inc.

Print
| Source: Dawson James Securities, Inc.

BOCA RATON, Fla., June 13, 2018 (GLOBE NEWSWIRE) -- Dawson James Securities, Inc.  and Maxim Group LLC acted as dealer-managers on an oversubscribed equity subscription rights offering for PAVmed Inc. (Nasdaq:PAVM) (Nasdaq:PAVMZ) which raised the maximum gross proceeds of $10,350,000 and closed on June 12th

Pursuant to the Rights Offering, PAVmed’s stockholders exercised, and the Company accepted equity subscription rights resulting in the issuance of 9 million units that consisted of one share of common stock and one Series Z Warrant.  Each right entitled the holder to purchase one unit at a subscription price of $1.15 per unit, with each unit consisting of one share of common stock (PAVM) and one Series Z Warrant (PAVMZ) to purchase one share of common stock with an exercise price of $1.60. 

The Company intends to use the net proceeds from the offering for general working capital and corporate purposes. 

Questions about the Rights Offering may be directed to Dawson James Securities, Inc., Attention: Prospectus Department, 1 North Federal Highway, 5th Floor, Boca Raton, FL 33432, via email at mmaclaren@dawsonjames.com or telephone (toll free) at (866) 928-0928.

The Rights Offering was made by means of a written prospectus pursuant to the Company’s effective registration statement on Form S-1 (File No. 333-222581) as filed with the SEC. The registration statement was declared effective by the SEC on May 23, 2018 and is available on the SEC’s web site at http://www.sec.gov. Copies of the written prospectus for the Rights Offering may be obtained by contacting Morrow Sodali Global LLC, the Information Agent for the Rights Offering, at:

Stockholders please call toll-free: (800) 662-5200
Banks and Brokerage Firms please call: (203) 658-9400
Email: PAVM.info@morrowsodali.com

About PAVmed

PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to advance innovative products to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its four lead products provide groundbreaking approaches to carpal tunnel syndrome (CarpX™), precancerous conditions of the esophagus (EsoCheck), vascular access (PortIO™) and pediatric ear infections (DisappEAR™). The company is also developing innovative products in other areas, such as medical infusions and tissue ablation, while seeking to further expand its pipeline through engagements with clinician innovators and leading academic medical centers. For further information, please visit www.pavmed.com.

About Dawson James Securities

Dawson James Securities specializes in capital raising for small and microcap public and private growth companies primarily in the Life Science/Health Care, Technology and Consumer sectors and is a full-service investment banking firm with research, institutional and retail sales, and execution trading and corporate services.  Headquartered in Boca Raton, FL, Dawson James is privately held with offices in New York, Maryland and New Jersey.  www.dawsonjames.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:  This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.  

Member FINRA/SIPC.   For more information, please contact:

Elise Stern, Managing Director, Head of Capital Markets
estern@dawsonjames.com
561-208-2926